Angiotensin converting enzyme inhibitor induced angio-oedema: a review of the pathophysiology and risk factors.

Détails

ID Serval
serval:BIB_F8075C70EC3E
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Titre
Angiotensin converting enzyme inhibitor induced angio-oedema: a review of the pathophysiology and risk factors.
Périodique
Clinical and Experimental Allergy
Auteur(s)
Hoover T., Lippmann M., Grouzmann E., Marceau F., Herscu P.
ISSN
0954-7894
Statut éditorial
Publié
Date de publication
2010
Peer-reviewed
Oui
Volume
40
Numéro
1
Pages
50-61
Langue
anglais
Résumé
Angio-oedema (AE) is a known adverse effect of angiotensin converting enzyme inhibitor (ACE-I) therapy. Over the past several decades, evidence of failure to diagnose this important and potentially fatal reaction is commonly found in the literature. Because this reaction is often seen first in the primary care setting, a review was undertaken to analyse and document the keys to both diagnostic criteria as well as to investigate potential risk factors for ACE-I AE occurrence. A general review of published literature was conducted through Medline, EMBASE, and the Cochrane Database, targeting ACE-I-related AE pathomechanism, diagnosis, epidemiology, risk factors, and clinical decision making and treatment. The incidence and severity of AE appears to be on the rise and there is evidence of considerable delay in diagnosis contributing to significant morbidity and mortality for patients. The mechanism of AE due to ACE-I drugs is not fully understood, but some genomic and metabolomic information has been correlated. Additional epidemiologic data and clinical treatment outcome predictors have been evaluated, creating a basis for future work on the development of clinical prediction tools to aid in risk identification and diagnostic differentiation. Accurate recognition of AE by the primary care provider is essential to limit the rising morbidity associated with ACE-I treatment-related AE. Research findings on the phenotypic indicators relevant to this group of patients as well as basic research into the pathomechanism of AE are available, and should be used in the construction of better risk analysis and clinical diagnostic tools for ACE-I AE.
Mots-clé
Dipeptidyl Peptidase-Iv, Bradykinin-Mediated Angioedema, Fresh-Frozen Plasma, C-Reactive Protein, Ace-Inhibitors, Hereditary Angioedema, Clinical-Experience, Angioneurotic-Edema, Gene Polymorphism, Aminopeptidase-P
Pubmed
Web of science
Création de la notice
07/10/2009 16:34
Dernière modification de la notice
03/03/2018 22:51
Données d'usage